Latest debt-to-equity ratio
Prelude Therapeutics Debt-to-equity ratio
Direct answer
Prelude Therapeutics's debt-to-equity ratio is 13.2%.
The verified market snapshot reports 13.2%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked September 12, 2026.
Get free Prelude Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 13.2%
Explore related company data
View Prelude Therapeutics's market capitalizationView Prelude Therapeutics's price-to-book ratioView Prelude Therapeutics's return on equityView Prelude Therapeutics's 52-week price rangeView Prelude Therapeutics's profit marginView all Prelude Therapeutics key metricsReturn to Prelude Therapeutics profile